Summit Therapeutics Inc (NAS:SMMT)
$ 13.66 -1.31 (-8.75%) Market Cap: 10.90 Bil Enterprise Value: 10.23 Bil PE Ratio: 0 PB Ratio: 16.82 GF Score: 27/100

Summit Therapeutics Inc at JPMorgan Healthcare Conference Transcript

Jan 12, 2026 / 05:45 PM GMT
Release Date Price: $17.04 (-13.41%)


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SMMT.OQ - Summit Therapeutics Inc
Summit Therapeutics Inc at JPMorgan Healthcare Conference
Jan 12, 2026 / 05:45PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon.

Thank you for joining us today and thank you for JP Morgan for having us, today to present at this conference. I'm Doctor Macky Zongane, President and co-CEO at, Summit Therapeutic. Bob Duggan, Chairman and CEO at Summit Therapeutic.

I'm honored to go over the latest update for Summit, our lead asset Iboisimab, as well as reviewing our upcoming catalyst for what we believe will be a positive, transformative year for Summit in 2026.

Summit and our partner ECESO have now completed 4 positive phase 3 studies with Ivanisimab, both in China with EESO and globally with Summit in setting either head to head against PD1 inhibitors or in setting where PD1 inhibitors have failed to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot